Rheumatology Division, ProteoRed/ISCIII Proteomics Group, INIBIC - Hospital Universitario de A Coruña.
CIBER-BBN Instituto de Salud Carlos III, INIBIC-CHUAC.
Curr Opin Rheumatol. 2018 Jan;30(1):114-120. doi: 10.1097/BOR.0000000000000460.
'Omics' technologies developed for the massive analysis of the major biologically relevant molecules (genes, proteins, metabolites) have been applied to the study of osteoarthritis (OA) for more than a decade.
'Omics' studies have undoubtedly contributed to increase the knowledge on pathogenic processes related with OA and have provided hundreds to thousands of molecules that might have a putative biomarker utility for this disease.
This review describes the most recent 'omics' studies in OA research, their conclusions, and discuss those remaining challenges. Still many validation studies must be performed in large and well-characterized cohorts for the translation of the findings from 'omics' strategies to clinical applications. The development of tools for the intelligent integration of 'omics' data with clinical and imaging information is also mandatory to take full profit of the work that has been already performed.
用于大规模分析主要生物学相关分子（基因、蛋白质、代谢物）的“组学”技术已应用于骨关节炎（OA）研究超过十年。
“组学”研究无疑增加了与 OA 相关发病机制过程的知识，并提供了数百到数千种可能对该疾病具有潜在生物标志物效用的分子。
本综述描述了 OA 研究中最新的“组学”研究、它们的结论，并讨论了那些仍然存在的挑战。仍需要在大型、特征明确的队列中进行大量验证研究，以便将“组学”策略的研究结果转化为临床应用。开发用于将“组学”数据与临床和影像学信息智能整合的工具也是充分利用已经完成的工作的必要条件。
